Battle of the milky way: Lymphatic targeted drug delivery for pathogen eradication.

Many viruses, bacteria, and parasites rely on the lymphatic system for survival, replication, and dissemination. While conventional anti-infectives can combat infection-causing agents in the bloodstream, they do not reach the lymphatic system to eradicate the pathogens harboured there. This can result in ineffective drug exposure and reduce treatment effectiveness. By developing effective lymphatic delivery strategies for antiviral, antibacterial, and antiparasitic drugs, their systemic pharmacokinetics may be improved, as would their ability to reach their target pathogens within the lymphatics, thereby improving clinical outcomes in a variety of acute and chronic infections with lymphatic involvement (e.g., acquired immunodeficiency syndrome, tuberculosis, and filariasis). Here, we discuss approaches to targeting anti-infective drugs to the intestinal and dermal lymphatics, aiming to eliminate pathogen reservoirs and interfere with their survival and reproduction inside the lymphatic system. These include optimized lipophilic prodrugs and drug delivery systems that promote lymphatic transport after oral and dermal drug intake. For intestinal lymphatic delivery via the chylomicron pathway, molecules should have logP values >5 and long-chain triglyceride solubilities >50 mg/g, and for dermal lymphatic delivery via interstitial lymphatic drainage, nanoparticle formulations with particle size between 10 and 100 nm are generally preferred. Insight from this review may promote new and improved therapeutic solutions for pathogen eradication and combating infective diseases, as lymphatic system involvement in pathogen dissemination and drug resistance has been neglected compared to other pathways leading to treatment failure.

Liposome-Micelle-Hybrid (LMH) Carriers for Controlled Co-Delivery of 5-FU and Paclitaxel as Chemotherapeutics.

Paclitaxel (PTX) and 5-fluorouracil (5-FU) are clinically relevant chemotherapeutics, but both suffer a range of biopharmaceutical challenges (e.g., either low solubility or permeability and limited controlled release from nanocarriers), which reduces their effectiveness in new medicines. Anticancer drugs have several major limitations, which include non-specificity, wide biological distribution, a short half-life, and systemic toxicity. Here, we investigate the potential of liposome-micelle-hybrid (LMH) carriers (i.e., drug-loaded micelles encapsulated within drug-loaded liposomes) to enhance the co-formulation and delivery of PTX and 5-FU, facilitating new delivery opportunities with enhanced chemotherapeutic performance. We focus on the combination of liposomes and micelles for co-delivery of PTX and 5_FU to investigate increased drug loading, improved solubility, and transport/permeability to enhance chemotherapeutic potential. Furthermore, combination chemotherapy (i.e., containing two or more drugs in a single formulation) may offer improved pharmacological performance. Compared with individual liposome and micelle formulations, the optimized PTX-5FU-LMH carriers demonstrated increased drug loading and solubility, temperature-sensitive release, enhanced permeability in a Caco-2 cell monolayer model, and cancer cell eradication. LMH has significant potential for cancer drug delivery and as a next-generation chemotherapeutic.

Role of Silica Intrawall Microporosity on Abiraterone Acetate Solubilization and In Vivo Oral Absorption.

SBA-15 mesoporous silica (MPS) has been widely used in oral drug delivery; however, it has not been utilized for solidifying lipid-based formulations, and the impact of their characteristic intrawall microporosity remains largely unexplored. Here, we derive the impact of the MPS microporosity on the in vitro solubilization and in vivo oral pharmacokinetics of the prostate cancer drug abiraterone acetate (AbA) when coencapsulated along with medium chain lipids into the pores. AbA in lipid (at 80% equilibrium solubility) was imbibed within a range of MPS particles (with comparable morphology and mesoporous structure but contrasting microporosity ranging from 0-247 m2/g), and their solid-state properties were characterized. Drug solubilization studies during in vitro lipolysis revealed that microporosity was the key factor in facilitating AbA solubilization by increasing the surface area available for drug-lipid diffusion. Interestingly, microporosity hindered hydrolysis of AbA to its active metabolite, abiraterone (Ab), under simulated intestinal conditions. This unique relationship between microporosity and AbA/Ab aqueous solubilization behavior was hypothesized to have significant implications on the subsequent bioavailability of the active metabolite. In vivo oral pharmacokinetics studies in male Sprague-Dawley rats revealed that MPS with moderate microporosity attained the highest relative bioavailability, while poor in vitro-in vivo correlations (IVIVC) existed between in vitro drug solubilization during lipolysis and in vivo AUC. Despite this, a reasonable IVIVC was established between the in vitro solubilization and in vivoCmax, providing evidence for an association between silica microporosity and oral drug absorption.

Insights into hydrophobic molecule release from polyelectrolyte multilayer films using in situ and ex situ techniques.

We report on the loading and release of curcumin (a hydrophobic polyphenol with anti-inflammatory and anti-bacterial properties) from polyelectrolyte multilayers composed of poly(diallyldimethylammonium chloride) (PDADMAC) and poly(sodium 4-styrenesulfonate) (PSS). We have used the in situ techniques of attenuated total reflectance (ATR) FTIR spectroscopy and quartz crystal microbalance with dissipation monitoring (QCM-D) to study the formation of the PEM and the incorporation of curcumin, providing direct evidence of the incorporation, in terms of molecular vibrations and gravimetric detection. The release of curcumin was followed using ex situ measurements of UV-visible spectroscopy of PEM films on quartz plates, in addition to in situ ATR FTIR measurements. Release was studied as a function of salt concentration of the release solution (0.001 M NaCl; 1 M NaCl). UV-visible spectroscopy indicated that salt concentration of the release solution had a major impact on release rates, with higher salt giving faster/more extensive release. However, prolonged timescale immersion and monitoring with UV-visible spectroscopy indicated that sample dehydration/rehydration cycling (required to measure UV absorbance) was responsible for the release of curcumin, rather than immersion time. In situ measurements of release kinetics with ATR FTIR confirmed that release does not occur spontaneously while the multilayer remains hydrated.

Spectroscopic investigation of the adsorption mechanisms of polyacrylamide polymers onto iron oxide particles.

The mechanisms of high-molecular-weight polyacrylamide nonionic homopolymer and 25 mol% anionic acrylate-substituted copolymer adsorption onto iron oxide particles were investigated via DRIFT and UV-vis spectroscopies at three pH values (6, 8.5, and 11). While electrostatic interactions play an important role in charged polymer adsorption, this information is not spectroscopically available. At pH values above and below pH 8.5 (the isoelectric point for the anionic polymer), bidentate chelation and hydrogen bonding were the main adsorption mechanisms. At the isoelectric point, monodentate chelation was observed to be the main mode of adsorption, along with hydrogen bonding. For the nonionic polymer, in all cases, hydrogen bonding through the carbonyl group was the main mode of adsorption. The adsorption of both polymers conformed well to the Freundlich model, suggesting that the adsorbed polymer amount increases with increasing polymer concentration up to 7500 g/t solid, rather than approaching monolayer coverage. Spectroscopic evidence was found to suggest that hydrolysis of nonionic polyacrylamide occurs at high pH.

Interfacial-chemistry mediated behavior of colloidal talc dispersions.

Interfacial chemistry and rheological behavior of talc suspensions as a function of pH, talc solid content, and type and concentration of ions have been investigated using electrokinetic measurements, rheology, settling behavior, and solution analysis. Zeta potential measurements show a strong dependence on the pH history of the talc suspension that only occurs when the surface area (solid content) of the talc is high. Particle interactions measured through dispersion yield stress measurements show a similar dependence. Talc is a magnesium silicate mineral and the dependence seen in the electrokinetic properties in this study has been attributed to Mg(II) dissolution at low pH, and has been confirmed by solution analysis. At high solid content (>20 wt%), pronounced Mg(II) ion dissolution occurs at low pH values. Formation and adsorption of electropositive Mg(II) hydrolysis products occurs at high pH (>9), and these lead to zeta potential reduction and, at high solid contents, charge reversal. Particle interactions reflect the surface chemistry behavior. Consequently, for a freshly prepared suspension at high pH, the yield stress is lower compared to after the pH has been taken to 5 and subsequently increased.